Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-09-30
2000-04-25
Yucel, Remy
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 235, 536 241, C07H 2104
Patent
active
060545704
ABSTRACT:
Over the past decade, it has become clear that tumorigenesis is driven by alterations in genes that control cell growth or cell death. Theoretically, the proteins encoded by these genes provide excellent tools for achieving tumor cell-specific expression. An approach to achieving specific expression of a desired protein in tumor cells is based on the selective expression of such oncoproteins. In outline, an endogenous cellular oncoprotein binds to exogenously introduced gene products, resulting in transcriptional activation of a desired gene. This approach is generally applicable to other diseases in which a particular protein is selectively expressed in disease-affected cells as compared to non-affected cells.
REFERENCES:
patent: 5866340 (1999-02-01), Vogelstein et al.
Moolten, F.L.Karp et al. An Alternative to the Magic Bullet Paradigm for Specific Cancer Therapy. Medical Hypothesis. 1987. vol. 24, pp. 43-51.
Karp et al. Nature Medicine 1:309-320 (1995).
Fields et al. Trends Genet. 10:286-292 (1994).
Gyuris et al.,Cell 75:791-803 (1993).
Germino et al., Proc. Natl. Acad. Sci. USA 90:933-937 (1993).
Hurford, R.K. et al., Gene Therapy of Metastatic Cancer by in vivo Retroviral Gene Targeting. Nature Genetics. Aug. 1995, vol. 10, pp. 430-435.
Verma et al. Nature, Sep. 18, 1997, vol. 389, pp. 239-242.
Barinaga, M. Science, vol. 266, p. 1326.
Marshall, E. Science, vol. 269, pp. 1050-1055.
Crystal, R.G. Sicence, vol. 270, pp. 404-410.
Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.
Jolly, D. Cancer Gene Tehrapy, vol. 1 (1)pp. 51-64.
Marshall, E.M. Science. vol. 269, pp. 1050-1055, Aug. 1995.
Crystal, R.G. Science. vol. 270, pp. 404-410, 1995.
Jolly, D. Cancer Gene Therapy, vol. 1(1), pp. 51-64, 1994.
Verma et al. Nature. vol. 389, pp. 239-242, Sep. 1997.
Nature Biotechnology, editorial. vol. 15, Sep. 1997.
Jarnoff, L. Time. vol. 153(1), pp. 68-73, Jan. 1999.
da Costa Luis
Jen Jin
Kinzler Kenneth W.
Vogelstein Bert
The Johns Hopkins University
Yucel Remy
LandOfFree
Selective expression of desired genes in cells expressing oncopr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective expression of desired genes in cells expressing oncopr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective expression of desired genes in cells expressing oncopr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-994329